Ipamorelin / CJC-1295 5mg / 5mg

This dual peptide combination pairs Ipamorelin, a growth hormone-releasing peptide (GHRP), with CJC-1295, a growth hormone-releasing hormone (GHRH) analog. The blend is studied for its synergistic effect on stimulating endogenous growth hormone release. Research focuses on receptor-mediated signaling, cellular hormone pathways, and downstream metabolic and endocrine responses.

• Growth hormone signaling studies
• Endocrine pathway research
• Cellular hormone regulation
• Metabolic and tissue repair studies
• Peptide-receptor interaction research

Research involving Ipamorelin / CJC-1295 is conducted under controlled laboratory conditions. Experimental cycles vary depending on study design, often including short-term signaling observations and longer-term metabolic or tissue response studies.

Dosing protocols are determined strictly within controlled research settings and vary based on peptide concentration, experimental objectives, and study design. Researchers calculate dosing based on targeted hormone release and study parameters.

This dual peptide is supplied as a lyophilized powder and may be reconstituted using bacteriostatic water or a sterile diluent. Reconstitution should be gradual and gentle to preserve peptide integrity. Standard sterile laboratory practices should be followed at all times.

• Store lyophilized product at 2–8°C
• For long-term storage, keep at -20°C
• Protect from light and moisture
• Avoid repeated freeze-thaw cycles

When stored properly in its lyophilized form, the peptide combination maintains stability over extended periods. Once reconstituted, the solution should be refrigerated and used within a limited timeframe in accordance with research protocols.

Tesamorelin
CJC-1295
Ipamorelin
Multi-peptide GHRH/GHRP formulations

For research purposes only. Not for human use. This product is not intended to diagnose, treat, cure, or prevent any disease.